(GPCR) Structure Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.567m USD | Total Return: 59% in 12m
Avg Turnover: 32.2M
Warnings
Share dilution 26.3% YoY
High Debt while negative Cash Flow
Altman Z'' -5.47 < 1.0 - financial distress zone
Tailwinds
Confidence
Structure Therapeutics Inc. (GPCR) is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for chronic metabolic and pulmonary diseases. The company’s primary focus is on G-protein coupled receptors (GPCRs), a class of membrane proteins that are the targets for approximately one-third of all FDA-approved drugs. Its lead candidate, GSBR-1290, is an oral GLP-1 receptor agonist currently undergoing Phase 2 clinical trials for the treatment of obesity and type 2 diabetes.
The company’s pipeline extends beyond GLP-1 treatments to include oral amylin receptor agonists and dual GLP-1R/GIPR agonists, aiming to provide non-injectable alternatives in the rapidly expanding metabolic health market. This business model relies on high-risk, high-reward drug discovery cycles where significant capital is deployed toward clinical validation before potential commercialization or partnership. Investors may find it useful to examine ValueRay for further data on biotechnology valuation trends.
In addition to metabolic health, Structure Therapeutics is developing treatments for idiopathic pulmonary fibrosis through its LTSE-2578 program. By utilizing a structure-based drug discovery platform, the firm seeks to design small molecules that can be manufactured more cost-effectively and administered more easily than traditional peptide-based biologics. The company is headquartered in South San Francisco’s biotechnology hub and maintains a global research footprint.
- Clinical trial data for oral GLP-1 receptor agonist GSBR-1290 drives valuation
- Competitive positioning against injectable obesity drugs impacts market share expectations
- Progression of early-stage amylin and GIPR pipeline candidates influences long-term growth
- Strategic partnership or acquisition interest from major pharmaceutical firms affects stock volatility
- Capital requirements for late-stage clinical trials dictate future dilution and cash runway
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA 5.17 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.10 > 3% & CFO -154.7m > Net Income -170.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 26.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (72.4m) vs 12m ago 26.32% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.21%; Δ -0.21% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.95 (Total Current Assets 1.49b - Total Current Liabilities 57.0m) / Total Assets 1.51b |
| B: -0.36 (Retained Earnings -546.3m / Total Assets 1.51b) |
| C: -0.16 (EBIT TTM -192.5m / Avg Total Assets 1.19b) |
| D: -8.99 (Book Value of Equity -548.4m / Total Liabilities 61.0m) |
| Altman-Z'' = -5.47 = D |
As of May 24, 2026, the stock is trading at USD 38.79 with a total of 466,951 shares traded.
Over the past week, the price has changed by +1.29%,
over one month by -15.72%,
over three months by -41.61% and
over the past year by +58.99%.
Structure Therapeutics has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy GPCR.
- StrongBuy: 8
- Buy: 6
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 106.5 | 174.5% |
Revenue TTM = 0.0 USD
EBIT TTM = -192.5m USD
EBITDA TTM = -190.3m USD
Long Term Debt = 3.18m USD (estimated: total debt 5.79m - short term 2.61m)
Short Term Debt = 2.61m USD (from shortTermDebt, last quarter)
Debt = 12.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 6.49m
Net Debt = -1.45b USD (calculated: Debt 12.3m - CCE 1.46b)
Enterprise Value = 1.12b USD (2.57b + Debt 12.3m - CCE 1.46b)
Interest Coverage Ratio = unknown (Ebit TTM -192.5m / Interest Expense TTM 0.0)
EV/FCF = -7.04x (Enterprise Value 1.12b / FCF TTM -159.2m)
FCF Yield = -14.21% (FCF TTM -159.2m / Enterprise Value 1.12b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 3.90m) / Revenue TTM)
Tobins Q-Ratio = 0.74 (Enterprise Value 1.12b / Total Assets 1.51b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 12.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -152.1m (EBIT -192.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 26.16 (Total Current Assets 1.49b / Total Current Liabilities 57.0m)
Debt / Equity = 0.01 (Debt 12.3m / totalStockholderEquity, last quarter 1.45b)
Debt / EBITDA = 7.60 (negative EBITDA) (Net Debt -1.45b / EBITDA -190.3m)
Debt / FCF = 9.09 (negative FCF - burning cash) (Net Debt -1.45b / FCF TTM -159.2m)
Total Stockholder Equity = 1.13b (last 4 quarters mean from totalStockholderEquity)
RoA = -14.37% (Net Income -170.6m / Total Assets 1.51b)
RoE = -10.20% (Net Income TTM -170.6m / Total Stockholder Equity 1.67b)
RoCE = -11.49% (EBIT -192.5m / Capital Employed (Equity 1.67b + L.T.Debt 3.18m))
RoIC = -69.51% (negative operating profit) (NOPAT -152.1m / Invested Capital 218.8m)
WACC = 11.41% (E(2.57b)/V(2.58b) * Re(11.46%) + D(12.3m)/V(2.58b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 21.89%
[DCF] Fair Price = unknown (Cash Flow -159.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.38 | Chg30d=+14.62% | Revisions=+20% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.15 | Chg30d=+68.06% | Revisions=-20% | Analysts=9
EPS current Year (2026-12-31): EPS=-1.37 | Chg30d=+7.90% | Revisions=+17% | GrowthEPS=-70.7% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.12 | Chg30d=+1.89% | Revisions=+9% | GrowthEPS=-55.1% | GrowthRev=-99.9%
[Analyst] Revisions Ratio: +20%